arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Travere Therapeutics, Inc.

TVTX Health Care Biotechnology: Pharmaceutical Preparations
$65.28
Today
as of Sep 4, 16:55 ET
Last 30 days +16.76% Jul 28 → Sep 04
$53.98 $57.61 $61.25 $64.89 $68.52 Jul 28 Aug 05 Aug 12 Aug 20 Aug 27 Sep 04
Open
$66.04
High
$67.11
Low
$65.04
Volume
$1M
Avg Vol
$2M
Mkt Cap
$5.8B
P/E (TTM)
—
Beta
—
52w High
$68.03
52w Low
$20.84
Div Yield
—
Shares Out
$94M

Recent Press Releases & News last 60 days · 21 items

Aug 21 · 17:09 Investor's Business Daily
IBD Stock Of The Day, Travere Therapeutics, Tests Another Breakout. Can The Stock Get Any 'Sweeter?'
Aug 18 · 10:01 MarketBeat
Travere Therapeutics Sees FILSPARI FSGS Launch Top Expectations, Expands Renal Pipeline
Aug 12 · 21:00 PR Business Wire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
▸ Show all 21 press releases & news Free account →

Overview

52-week range
$21
$68
94% of range
Avg surprise (last 3)
+11.5%
Avg reaction (last 2)
+0.8%
50% positive
Latest IV / EM
37%
EM ±5.8% · $65 · Sep 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$-1.76$-0.83$0.10$1.04$1.97 Actual $-1.27Actual $-1.13Actual $1.97Actual $-1.76Actual $-0.91Actual $-0.70Actual $-0.47Est $-0.55Actual $-0.14Est $-0.28Actual $0.28Actual $-0.39Est $-0.30Actual $-0.37 MarJunSepMarJunSepMar/2025Jun/2025SepMar/2026Jun
Revenue vs Net Income Revenue Net income
$-55M$3M$62M$120M$178M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.37 — — — — financials
Mon May 4, 2026Mar/2026 $-0.39 $-0.30 -30.0% +17.0% +1.8% earnings
Tue Sep 30, 2025Sep 2025 $0.28 — — — — financials
Wed Aug 6, 2025Jun/2025 $-0.14 $-0.28 +50.0% — — earnings
Thu May 1, 2025Mar/2025 $-0.47 $-0.55 +14.6% — -0.2% earnings
Mon Sep 30, 2024Sep 2024 $-0.70 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.91 — — — — financials
Sun Mar 31, 2024Mar 2024 $-1.76 — — — — financials
Sat Sep 30, 2023Sep 2023 $1.97 — — — — financials
Fri Jun 30, 2023Jun 2023 $-1.13 — — — — financials
Fri Mar 31, 2023Mar 2023 $-1.27 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$170M$127M—$165M$114M$82M—$63M
Cost of revenue$2M$2M—$2M$2M$5M—$2M
Gross profit————————
Operating income$4M$-37M—$25M$-13M$-43M—$-56M
Net income$-35M$-37M—$26M$-13M$-41M—$-55M
EPS (diluted)$-0.37$-0.40—$0.28$-0.14$-0.47—$-0.70

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$118M$78M$93M$111M$75M$62M$59M$36M
Inventory$40M$37M$36M$38M$38M$38M$42M$43M
Total current assets$615M$393M$438M$371M$380M$374M$417M$325M
Total assets$799M$555M$605M$539M$555M$549M$594M$504M
Long-term debt————————
Total liabilities$775M$456M$490M$465M$523M$516M$535M$535M
Total equity$25M$99M$115M$74M$33M$33M$59M$-30M

Implied volatility — last 90 days

37%53%69%85%101% Jun 07 — IV 67% · EM ±9.3%Jun 08 — IV 60% · EM ±8.0%Jun 09 — IV 58% · EM ±7.3%Jun 10 — IV 74% · EM ±8.7%Jun 11 — IV 55% · EM ±6.1%Jun 12 — IV 68% · EM ±7.0%Jun 15 — IV 82% · EM ±5.9%Jun 16 — IV 73% · EM ±4.3%Jun 17 — IV 102% · EM ±4.2%Jun 19 — IV 49% · EM ±10.7%Jun 22 — IV 51% · EM ±10.7%Jun 23 — IV 48% · EM ±9.8%Jun 24 — IV 53% · EM ±10.6%Jun 25 — IV 56% · EM ±11.1%Jun 26 — IV 59% · EM ±11.2%Jun 29 — IV 58% · EM ±10.3%Jun 30 — IV 56% · EM ±9.7%Jul 01 — IV 54% · EM ±9.0%Jul 02 — IV 52% · EM ±8.3%Jul 03 — IV 53% · EM ±8.3%Jul 06 — IV 58% · EM ±8.0%Jul 07 — IV 58% · EM ±7.7%Jul 08 — IV 71% · EM ±8.9%Jul 09 — IV 62% · EM ±7.3%Jul 10 — IV 81% · EM ±9.0%Jul 13 — IV 99% · EM ±8.3%Jul 14 — IV 69% · EM ±5.0%Jul 15 — IV 69% · EM ±4.1%Jul 16 — IV 63% · EM ±2.6%Jul 20 — IV 69% · EM ±16.3%Jul 21 — IV 65% · EM ±15.1%Jul 22 — IV 66% · EM ±15.1%Jul 23 — IV 75% · EM ±16.8%Jul 24 — IV 75% · EM ±16.5%Jul 27 — IV 62% · EM ±13.0%Jul 28 — IV 75% · EM ±15.2%Jul 29 — IV 69% · EM ±13.8%Jul 30 — IV 77% · EM ±15.1%Jul 31 — IV 75% · EM ±14.4%Aug 03 — IV 84% · EM ±14.8%Aug 04 — IV 89% · EM ±15.3%Aug 05 — IV 56% · EM ±9.3%Aug 06 — IV 58% · EM ±9.4%Aug 07 — IV 44% · EM ±6.8%Aug 10 — IV 55% · EM ±7.7%Aug 11 — IV 60% · EM ±8.0%Aug 12 — IV 47% · EM ±5.9%Aug 13 — IV 53% · EM ±6.3%Aug 14 — IV 52% · EM ±5.8%Aug 17 — IV 61% · EM ±5.1%Aug 18 — IV 72% · EM ±5.2%Aug 19 — IV 86% · EM ±5.1%Aug 20 — IV 79% · EM ±3.3%Aug 24 — IV 45% · EM ±9.4%Aug 25 — IV 48% · EM ±9.8%Aug 26 — IV 46% · EM ±9.3%Aug 27 — IV 43% · EM ±8.5%Aug 28 — IV 48% · EM ±9.2%Aug 31 — IV 41% · EM ±7.2%Sep 01 — IV 42% · EM ±7.3%Sep 02 — IV 41% · EM ±6.8%Sep 03 — IV 38% · EM ±6.1%Sep 04 — IV 37% · EM ±5.8%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in